This clinical quality registry aims to improve myeloma outcomes by providing an evidence base for the best strategies to diagnose, treat and support people with myeloma and related diseases.
Patients with multiple myeloma
Number of approved sites
The MRDR supports Rare Disease Day 2023 😊Read more
The MRDR has reached 5800 registered patients!Read more
Paper on the second revision of the International Staging System (R2-ISS) accepted for publication!Read more
The MRDR was recently represented at the 4th National Myeloma Workshop.Read more